P21 Research: What 52 Studies Show (2026) | RetatrutideCompare

P21 — 52 studies indexed on PubMed. Mimics CNTF activity via gp130 receptor signaling; promotes neurogenesis in hippocampal subgranular zone. Half-life: Hours. FDA status: Not FDA-approved.

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on P21?

There are approximately 52 studies indexed on PubMed that mention P21 (Ciliary Neurotrophic Factor mimetic peptide), based on a search last updated 2026-06-18.

Is P21 FDA-approved?

FDA status: Not FDA-approved.

How does P21 work?

Mimics CNTF activity via gp130 receptor signaling; promotes neurogenesis in hippocampal subgranular zone.

Reference facts

Also known as: Ciliary Neurotrophic Factor mimetic peptide
Category: Nootropic & Cognitive
Mechanism of action: Mimics CNTF activity via gp130 receptor signaling; promotes neurogenesis in hippocampal subgranular zone.
Targets: gp130 (CNTF receptor)
Indications under research or approved: Preclinical research — neurodegeneration, neurogenesis
Regulatory status (reference entry): Not FDA-approved
Half-life: Hours
Sequence: DGGLAG
Sequence notes: Hexapeptide CNTF mimetic with N-acetyl and C-amide modifications.
Molecular weight (Da): 503
First reported: 2010

Primary References

Blanchard et al., Neuropeptides 2010 (P21 neurogenesis)

Explore research articles about P21

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.